Neoadjuvant chemotherapy in breast cancer in the last 2 decades: Are we improving survival? Retrospective analysis in a single institution

Por: Ponce, J, Delgado, S, Ballester, H, Martin, T, Peiro, G, Aranda, F, Niveiro, M, Montoyo, Y, Gomez, N, Sanchez, J, Rodriguez-Lescure, A, Parra, D, Gomez, L, Lozano, I and Massuti, B

---

Publicada: 1 may 2021 Ahead of Print: 1 may 2021

---

---

Filiaciones:
Ponce, J:
 Hosp Gen Univ Alicante, Med Oncol, ISABIAL, Alicante, Spain

Delgado, S:
 Hosp Gen Univ Alicante, Obstet & Gynaecol, ISABIAL, Alicante, Spain

Ballester, H:
 Hosp Gen Univ Alicante, Obstet & Gynaecol, ISABIAL, Alicante, Spain

Martin, T:
 Hosp Gen Univ Alicante, Obstet & Gynaecol, ISABIAL, Alicante, Spain

Aranda, F:
 Hosp Gen Univ Alicante, Pathol, ISABIAL, Alicante, Spain

Niveiro, M:
 Hosp Gen Univ Alicante, Pathol, ISABIAL, Alicante, Spain

Montoyo, Y:
 Hosp Gen Univ Alicante, Res Unit, ISABIAL, Alicante, Spain

Gomez, N:
 Hosp Gen Univ Alicante, Res Unit, ISABIAL, Alicante, Spain

Sanchez, J:
 Hosp Gen Univ Alicante, Res Unit, ISABIAL, Alicante, Spain

:
 Hosp Gen Univ Elche, Med Oncol, GEICAM, Spanish Breast Canc Grp, Elche, Spain

Parra, D:
 Hosp Gen Univ Alicante, Med Oncol, ISABIAL, Alicante, Spain

Gomez, L:
 Hosp Gen Univ Alicante, Med Oncol, ISABIAL, Alicante, Spain

Lozano, I:
 Hosp Gen Univ Alicante, Med Oncol, ISABIAL, Alicante, Spain

Massuti, B:
 Hosp Gen Univ Alicante, Med Oncol, ISABIAL, Alicante, Spain